Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action
Sheng-Min Wang, Changsu Han, Soo-Jung Lee, Ashwin A Patkar, Prakash S Masand, Chi-Un Pae
Psychiatry Investig. 2015;12(2):155-163.   Published online 2015 Mar 18     DOI:
Involvement of kynurenine pathway and N-methyl-d-aspartate receptors in the antidepressant-like effect of vilazodone in the tail suspension test in mice
Cristina Maria de Arruda, Diego Luiz Doneda, Vinícius Vezzi de Oliveira, Rozielly Aparecida Lemes da Silva, Yohan Alves Victor de Matos, Isadora Luiza Fernandes, Christopher Alecsander Herane Rohden, Giordano Gubert Viola, Fabrício Rios-Santos, Eliângela
Pharmacology Biochemistry and Behavior.2022; 218: 173433.     CrossRef
Vilazodone-phospholipid mixed micelles for enhancing oral bioavailability and reducing pharmacokinetic variability between fed and fasted states
Hala S. El Said, Aikaterini Lalatsa, Abdulaziz M. Al-Mahallawi, Eman Saddar El Leithy, Dalia M. Ghorab
International Journal of Pharmaceutics.2022; 625: 122080.     CrossRef
Consistency Is Critical for the Effective Use of Baited Remote Video
Robyn E. Jones, Ross A. Griffin, Roger J. H. Herbert, Richard K. F. Unsworth
Oceans.2021; 2(1): 215.     CrossRef
Nitrile-containing pharmaceuticals: target, mechanism of action, and their SAR studies
Xi Wang, Yuanxun Wang, Xuemin Li, Zhenyang Yu, Chun Song, Yunfei Du
RSC Medicinal Chemistry.2021; 12(10): 1650.     CrossRef
Comparative evaluation of efficacy and tolerability of vilazodone, escitalopram, and amitriptyline in patients of major depressive disorder: A randomized, parallel, open-label clinical study
RenukaL Kadam, SmitaDipak Sontakke, Prashant Tiple, VijayM Motghare, ChaitaliS Bajait, MrunaliniV Kalikar
Indian Journal of Pharmacology.2020; 52(2): 79.     CrossRef
In silico decryption of serotonin–receptor binding: local non-covalent interactions and long-range conformational changes
Padmabati Mondal
RSC Advances.2020; 10(62): 37995.     CrossRef
New Treatment Options for Depression: A Primer for Internists
Tina H. Byun, Swarna S. Chaliki, Kenneth G. Poole
The American Journal of Medicine.2019; 132(6): 678.     CrossRef
Differences Between the Prenatal Effects of Fluoxetine or Buspirone Alone or in Combination on Pain and Affective Behaviors in Prenatally Stressed Male and Female Rats
Irina P. Butkevich, Viktor A. Mikhailenko, Elena A. Vershinina, Gordon A. Barr
Frontiers in Behavioral Neuroscience.2019;[Epub]     CrossRef
Research on Network Service Management Platform for Long Term Mechanism of Sports in Colleges
Hongyuan He, Tao He, Gang Peng
Wireless Personal Communications.2018; 102(2): 1117.     CrossRef
Addressing the Side Effects of Contemporary Antidepressant Drugs: A Comprehensive Review
Sheng-Min Wang, Changsu Han, Won-Myoung Bahk, Soo-Jung Lee, Ashwin A. Patkar, Prakash S. Masand, Chi-Un Pae
Chonnam Medical Journal.2018; 54(2): 101.     CrossRef
5-HT1A receptor ligands and their therapeutic applications: review of new patents
Jakub Staroń, Ryszard Bugno, Adam S. Hogendorf, Andrzej J. Bojarski
Expert Opinion on Therapeutic Patents.2018; 28(9): 679.     CrossRef
Shortened Spadin Analogs Display Better TREK-1 Inhibition, In Vivo Stability and Antidepressant Activity
Alaeddine Djillani, Mariel Pietri, Sébastien Moreno, Catherine Heurteaux, Jean Mazella, Marc Borsotto
Frontiers in Pharmacology.2017;[Epub]     CrossRef
Identification and characterization of vilazodone metabolites in rats and microsomes by ultrahigh-performance liquid chromatography/quadrupole time-of-flight tandem mass spectrometry
Balasaheb B. Chavan, Pradipbhai D. Kalariya, Shristy Tiwari, Rakesh D. Nimbalkar, Prabha Garg, R. Srinivas, M.V.N. Kumar Talluri
Rapid Communications in Mass Spectrometry.2017; 31(23): 1974.     CrossRef
Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: A meta-analysis
Nicholas Zareifopoulos, Irene Dylja
Asian Journal of Psychiatry.2017; 26: 115.     CrossRef
New drugs in psychiatry: focus on new pharmacological targets
Filippo Caraci, Gian Marco Leggio, Salvatore Salomone, Filippo Drago
F1000Research.2017; 6: 397.     CrossRef
Vilazodone for major depressive disorder in adults
Lin Song, Yao Liu, Fang Liu, Ruoqi Zhang, Huanhuan Ji, Yuntao Jia
Cochrane Database of Systematic Reviews.2016;[Epub]     CrossRef
P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood–brain barrier in vivo
Christoffer Bundgaard, Elin Eneberg, Connie Sánchez
Neuropharmacology.2016; 103: 104.     CrossRef
Vilazodone for the Treatment of Depression: An Update
Sheng-Min Wang, Changsu Han, Soo-Jung Lee, Ashwin A. Patkar, Prakash S Masand, Chi-Un Pae
Chonnam Medical Journal.2016; 52(2): 91.     CrossRef
Optimizing the Use of Aripiprazole Augmentation in the Treatment of Major Depressive Disorder: From Clinical Trials to Clinical Practice
Changsu Han, Sheng-Min Wang, Soo-Jung Lee, Tae-Youn Jun, Chi-Un Pae
Chonnam Medical Journal.2015; 51(2): 66.     CrossRef
Five potential therapeutic agents as antidepressants: a brief review and future directions
Sheng-Min Wang, Changsu Han, Soo-Jung Lee, Ashwin A Patkar, Prakash S Masand, Chi-Un Pae
Expert Review of Neurotherapeutics.2015; 15(9): 1015.     CrossRef
Vilazodone: A Review in Major Depressive Disorder in Adults
Paul L. McCormack
Drugs.2015; 75(16): 1915.     CrossRef
Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: A 6-week, randomized, rater-blinded,prospective study
Changsu Han, Sheng-Min Wang, Kyung-Phil Kwak, Wang-Yeon Won, HwaYoung Lee, Chia Ming Chang, Tze Chun Tang, Chi-Un Pae
Journal of Psychiatric Research.2015; 66-67: 84.     CrossRef
Dominios cognitivos en la depresión unipolar. Teorías multimodales y nuevas perspectivas terapéuticas
Cristóbal Gastó, Joana Guarch, Víctor Navarro
Psiquiatría Biológica.2015; 22(2): 33.     CrossRef